Skip to content

Comparison of Bupivacaine Liposomes and Ropivacaine Continuous Nerve Block for Accelerated Recovery in Geriatric Hip Replacement Surgery

Comparison of Bupivacaine Liposomes and Ropivacaine Continuous Nerve Block for Accelerated Recovery in Geriatric Hip Replacement Surgery

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400091379
Enrollment
Unknown
Registered
2024-10-28
Start date
2024-11-01
Completion date
Unknown
Last updated
2024-11-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hip Fracture

Interventions

Bupivacaine Liposome Injection Analgesia Group:Under ultrasound guidance, the needle tip is positioned in the ilioinguinal compartment, and after negative aspiration for blood, 2 ml of normal saline i
Continuous Ilioinguinal Nerve Block Analgesia Group:Under ultrasound guidance, the needle tip is advanced to the ilioinguinal compartment. After negative aspiration to ensure no blood return, 2 ml of

Sponsors

The First People's Hospital of Bengbu City
Lead Sponsor

Eligibility

Sex/Gender
All
Age
60 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Patients aged 60 to 80 years 2. Elective total hip arthroplasty candidates 3. Anticipated hospital stay of more than 3 days 4. Patients undergoing neural blockade 5. Patients utilizing a postoperative analgesic pump

Exclusion criteria

Exclusion criteria: 1. Patients with hepatic or renal dysfunction (liver enzyme concentrations and serum creatinine at twice the normal value or more); 2. Patients allergic or suspected to be allergic to bupivacaine; 3. Patients with coagulation disorders; 4. Patients with diminished intelligence or cognitive dysfunction that prevents cooperation or communication; 5. Patients with long-term opioid use, drug addicts

Design outcomes

Primary

MeasureTime frame
Postoperative Recovery Quality;

Secondary

MeasureTime frame
Serum Inflammatory Cytokine (Interleukin-6 and Tumor Necrosis Factor-alpha) Levels;Hospitalization Days;Postoperative Cognitive Function;

Countries

China

Contacts

Public ContactHui Xu

The First People's Hospital of Bengbu City

bbxuhui@hotmail.com+86 138 6502 8488

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026